ADUS - Addus HomeCare Corp Options
This article provides a detailed financial overview of Addus HomeCare Corp (ADUS), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists performance metrics such as EPS growth, sales growth, insider/institutional ownership, profitability, and stock performance over different periods.
Precision Trading with Addus Homecare Corporation (ADUS) Risk Zones
This article provides an in-depth analysis of Addus Homecare Corporation (ADUS) with a focus on risk zones and trading strategies based on AI models. It highlights the stock's strong near and mid-term sentiment, weak long-term outlook, and outlines specific position, momentum breakout, and risk-hedging trading strategies with entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal strength, support, and resistance levels for various time horizons.
Price to earnings forward of Addus HomeCare Corporation – NASDAQ:ADUS
This article provides financial information for Addus HomeCare Corporation (NASDAQ: ADUS), specifically focusing on its forward price-to-earnings ratio. It indicates that the company's market is currently closed with no trades. The article is part of TradingView's platform, offering various financial tools and data.
Price to sales forward of Addus HomeCare Corporation – NASDAQ:ADUS
This article provides the "Price to sales forward" metric for Addus HomeCare Corporation (NASDAQ: ADUS). It briefly displays "Period", "Value", "Change", and "Change %" but the values themselves are not shown in the provided content. The content primarily comes from TradingView, indicating financial data for the company.
Addus HomeCare stock. Generalized focus holds on home care demand.
Addus HomeCare's stock performance is linked to its home-based care model, serving an aging U.S. demographic. The company provides personal care, hospice, and home health services, focusing on caregiver retention and local demand within a staffing-intensive healthcare sector. Its revenue is influenced by labor availability, referral volumes, and Medicaid reimbursement trends.
ADUS - Addus HomeCare Corp Forecast, Target Price
This article provides a detailed financial overview and forecast for Addus HomeCare Corp (ADUS) as of July 2nd. It includes key financial metrics such as market cap, income, sales, price-to-earnings ratios, and growth rates. The data also covers insider and institutional ownership, profitability, stock performance, and analyst recommendations with a target price.
Addus HomeCare Corporation(NasdaqGS:ADUS) dropped from Russell Small Cap Comp Growth Benchmark
Addus HomeCare Corporation (NasdaqGS:ADUS) has been removed from the Russell Small Cap Comp Growth Benchmark. This news comes alongside other announcements of ADUS being dropped from several Russell growth benchmarks, including the Russell 2500 Growth and Russell 2000 Growth benchmarks. The company provides home care services, with segments in Personal Care, Hospice, and Home Health.
The Bull Case For Addus HomeCare (ADUS) Could Change Following Russell Growth Index Removal – Learn Why
Addus HomeCare (ADUS) was recently removed from several Russell Growth indices, including the Russell 3000 Growth and Russell 2000 Growth. While this primarily impacts near-term trading liquidity rather than fundamentals, it prompts investors to reassess the company's investment narrative and risk profile. Despite solid Q1 2026 results and a projected fair value of $142.91, the index removal may influence how analysts and investors view its future growth and valuation.
Addus HomeCare Corporation Actuals & Estimates (NASDAQ:ADUS)
This article provides an in-depth financial overview of Addus HomeCare Corporation (NASDAQ: ADUS), including its current stock price, analyst forecasts, and historical performance. It details the company's financial actuals and estimates, covering income statements, balance sheets, and cash flow, alongside answers to frequently asked questions about its market capitalization, earnings, revenue, and volatility.
ADUS Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Addus HomeCare Corporation (ADUS) stock, including analyst ratings and future price predictions. It details the company's financial performance, such as revenue and EPS, and addresses frequently asked questions about its stock price, market capitalization, and earnings reports. The information is presented by TradingView and includes various financial metrics and technical analysis signals.
Addus HomeCare (ADUS) Could Be 4% Undervalued On Medicaid Funding Risk
Addus HomeCare (ADUS) stock is considered modestly undervalued at $96.86, with a narrative fair value of $100.85, primarily due to anticipated steady revenue expansion and stronger profit margins. However, this valuation is contingent on the risk of significant government healthcare spending cuts impacting critical Medicaid and Medicare funding. The company’s diverse revenue streams from personal care, hospice, and home health services operate entirely within the United States.
UBS Maintains Addus HomeCare(ADUS.US) With Buy Rating, Maintains Target Price $145
UBS analyst A.J. Rice has reaffirmed a Buy rating for Addus HomeCare (ADUS.US), maintaining a target price of $145. According to TipRanks data, this analyst boasts a 59.2% success rate and an average return of 8.2% over the past year. This report emphasizes that the information is for informational purposes only and not an investment recommendation.
Addus HomeCare president & COO sells $27,005 in stock By Investing.com
Heather Brianne Dixon, President and COO of Addus HomeCare Corp (NASDAQ:ADUS), sold 288 shares worth $27,005 on June 22, 2026, to cover tax obligations from restricted stock awards. This transaction was part of a pre-established trading plan. Following the sale, Dixon directly holds 44,371 shares of the company.
Addus HomeCare president & COO sells $27,005 in stock
Heather Brianne Dixon, President and COO of Addus HomeCare Corp, sold 288 shares worth $27,005 on June 22, 2026, to cover tax obligations from restricted stock awards. This transaction occurred via a pre-established 10b5-1 trading plan. The company's stock is considered undervalued by InvestingPro analysis, despite a revenue growth of 19.6% over the last year, and recently reported strong Q1 2026 EPS but slightly missed revenue estimates.
Tax-driven sale by Addus HomeCare (ADUS) president under 10b5-1 plan
Addus HomeCare Corp's President and COO, Heather Brianne Dixon, sold 288 shares of common stock at $93.77 per share under a Rule 10b5-1 trading plan. This sale was conducted to cover tax obligations arising from the vesting of restricted stock awards, as detailed in an SEC Form 4 filing. Following the transaction, Dixon retains 44,371 shares of Addus HomeCare common stock.
TD Cowen Maintains Addus HomeCare(ADUS.US) With Buy Rating, Maintains Target Price $131
TD Cowen has reiterated its Buy rating for Addus HomeCare (ADUS.US) and maintained its price target of $131. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Addus Homecare Corp (ADUS) Earnings Forecast: Future EPS & Revenue Growth Estimates
Addus Homecare Corp (ADUS) has an earnings forecast score of 8.29, ranking 22nd in the Healthcare Providers & Services industry. Analysts project a price target of $142.50, with a strong "Buy" rating based on 14 analysts. The company's expected revenue for the next quarter is $376.21 million, and EPS for the next quarter is anticipated to be $1.69.
Addus Homecare Corp (ADUS) Institutional Confidence
Addus Homecare Corp (ADUS) has an institutional confidence score of 10.00, placing it first in the Healthcare Providers & Services industry. The institutional shareholding proportion is 103.83%, a decrease of 6.34% quarter-over-quarter. ETHSX is the largest institutional shareholder, holding 1.98% of outstanding shares.
Addus Homecare Corp (ADUS) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides historical dividend and stock split information for Addus Homecare Corp (ADUS). It states that the company has distributed a total of $0.00 in dividends over the past five years and reports no data for stock splits. The page also presents current stock performance metrics and market capitalization for ADUS.
Addus Homecare Corp (ADUS) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Addus Homecare Corp (ADUS), listing major institutional holders and their proportions. It provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent shareholder activity with specific changes in holdings and proportions. The report also includes related ETFs that hold ADUS stock.
Possible Bearish Signals With Addus HomeCare Insiders Disposing Stock
The article highlights insider selling activity at Addus HomeCare, noting that over the last year, more shares were sold than bought. This could be interpreted as a bearish signal by investors, suggesting that company insiders might believe the stock is overvalued or anticipate future challenges. The largest individual sale was by Non-Executive Chairman Kevin Stevenson, who sold stock worth US$635k.
Healthcare Stocks to Avoid: Lantheus, Merit Medical, Addus HomeCare Analysis - News and Statistics
A recent analysis warns investors about three healthcare stocks – Lantheus Holdings (LNTH), Merit Medical Systems (MMSI), and Addus HomeCare (ADUS) – despite the sector matching the S&P 500's performance. The report highlights increased competition from venture capital influx, suggesting that only a few companies will achieve long-term growth. The featured companies show issues such as muted revenue growth, declining sales projections, rising costs, subscale revenue bases, and stagnant returns on invested capital.
Addus HomeCare (ADUS) director awarded 1,449 restricted shares vesting in 2027
Darin J. Gordon, a director at Addus HomeCare Corp (ADUS), was granted 1,449 restricted shares of common stock as compensation for non-employee director service. These shares, with no cash exercise price, will vest in full on June 10, 2027, increasing his direct holdings to 14,244 shares. The transaction was reported in a Form 4 filing, emphasizing transparency of insider trading.
Addus HomeCare Corp (ADUS) director awarded 1,449 restricted shares vesting 2027
Addus HomeCare Corp (ADUS) director Mark L. First was granted 1,449 restricted shares of common stock as compensation for his non-employee director service. These shares were awarded at no cash cost and will fully vest on June 10, 2027. Following this grant, Mark L. First directly holds a total of 15,070 shares of Addus HomeCare common stock.
Addus HomeCare (ADUS) director receives 1,449-share restricted stock grant
Addus HomeCare Corp director Veronica Hill-Milbourne was granted 1,449 restricted common shares as equity compensation, increasing her direct holdings to 6,516 shares. These shares were awarded at no purchase price and will fully vest on June 10, 2027, aligning her compensation with the company's future performance. This transaction is a stock grant, not an open-market purchase, and is detailed in a Form 4 SEC filing.
Addus HomeCare (ADUS) director awarded 1,449 restricted shares vesting in 2027
Addus HomeCare Corp. director Susan T. Weaver was granted 1,449 restricted shares of common stock as compensation, which will vest in full on June 10, 2027. This award is a routine equity component for non-employee directors, aligning their interests with shareholders. Following the grant, Weaver now directly holds 13,744 shares of Addus HomeCare common stock.
[8-K] Addus HomeCare Corp Reports Material Event
Addus HomeCare Corporation reported the results of its 2026 annual stockholder meeting, where shareholders elected Michael Earley and Veronica Hill-Milbourne as Class II directors, ratified PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026, and approved the compensation of named executive officers on an advisory basis. A significant majority of outstanding shares were represented at the meeting.
Citizens cuts Addus HomeCare stock price target on revenue miss
Citizens has lowered its price target for Addus HomeCare shares to $142 from $150, while maintaining a Market Outperform rating, following the company's first-quarter 2026 results. Although consolidated revenue exceeded Citizens' estimate, it fell short of consensus expectations, primarily due to hospice revenue missing projections. Despite mixed results and a dip in stock price, InvestingPro data indicates the stock is currently undervalued based on its P/E and PEG ratios, with a "GREAT" financial health score.
Addus HomeCare stock hits 52-week low at 89.76 USD By Investing.com
Addus HomeCare Corporation (ADUS) stock recently hit a 52-week low of $89.76, marking a 24% decline over six months and trading 28% below its high. Despite downward revisions in earnings by six analysts, InvestingPro analysis suggests the stock may be undervalued with a P/E ratio of 16.76 and a PEG ratio of 0.74, presenting a potential opportunity for investors. In related news, Q1 2026 EPS beat estimates, though revenue fell slightly short, leading Citizens to maintain a "Market Outperform" rating with a revised price target.
Addus HomeCare stock hits 52-week low at 89.76 USD
Addus HomeCare Corporation's stock has reached a 52-week low of $89.76, marking a 24% decrease over six months and a 28% drop from its 52-week high. Despite six analysts revising earnings forecasts downwards, InvestingPro suggests the stock is undervalued, presenting a potential opportunity for investors. The company recently reported Q1 2026 EPS exceeding expectations, though revenue missed consensus.
Addus HomeCare stock hits 52-week low at 89.76 USD By Investing.com
Addus HomeCare Corporation's stock has fallen to a 52-week low of $89.76, representing a 24% decline over the past six months. Despite this downturn and downward revisions from analysts, InvestingPro suggests the stock may be undervalued with a P/E ratio of 16.76 and a PEG ratio of 0.74. The company recently reported better-than-expected Q1 2026 EPS but missed revenue forecasts, leading Citizens to maintain a "Market Outperform" rating with a reduced price target.
Addus HomeCare Corp stock (US0067391062): shares steady as investors look beyond recent volatility
Addus HomeCare Corp (ADUS) shares have been trading sideways with investors reassessing the company's position in the US home-care market after recent financial updates, according to Nasdaq pricing data. The stock's muted price action contrasts with broader healthcare underperformance, but analysts maintain a premium valuation due to Addus's defensive earnings and exposure to aging demographics. Future performance will depend on execution and reimbursement dynamics.
Addus HomeCare (ADUS) director Esteban Lopez sells 250 common shares at $93
Addus HomeCare Corp director Esteban Lopez sold 250 shares of the company's common stock at $93.00 per share in an open-market transaction on May 21, 2026. Following this sale, Lopez directly owns 3,200 shares of Addus HomeCare common stock. The transaction, reported via a Form 4 SEC filing, represents a net sale of 250 shares valued at $23,250.
Addus HomeCare (ADUS) director sells 250 common shares in open market
Addus HomeCare (ADUS) director Esteban Lopez reported an open-market sale of 250 common shares at a price of $93.00 per share on May 19, 2026. Following this transaction, Lopez directly holds 3,450 shares of Addus HomeCare common stock. The sale, valued at $23,250, was detailed in a Form 4 SEC filing.
Addus HomeCare Pursues Personal Care M&A As Shares Trade Below Targets
Addus HomeCare is actively pursuing mergers and acquisitions in personal care services, leveraging a strong balance sheet to target growth avenues outside federal moratoriums on certain home health licenses. The company's shares are currently trading below analyst targets and Simply Wall St's fair value estimate, reflecting recent share price pressure despite operational improvements and strategic M&A focus. Investors are advised to monitor acquisition details, personal care revenue mix, and the impact of technology on caregiver utilization and margins, while acknowledging execution risk.
Addus HomeCare Pursues Personal Care M&A As Shares Trade Below Targets
Addus HomeCare is focusing on personal care services expansion through mergers and acquisitions, supported by a strong balance sheet and limited impact from federal moratoriums. Despite recent share price pressure, the company is undervalued according to Simply Wall St, trading 30% below analyst targets. Key considerations for investors include monitoring acquisition execution, personal care revenue mix, and the effect of technology investments on caregiver utilization and margins.
Moratorium unlikely to hurt Addus’ M and A efforts, CEO Allison says
Dirk Allison, CEO of Addus HomeCare, stated that a new six-month Medicare enrollment moratorium for hospices and home care agencies is unlikely to affect Addus's operations or its merger and acquisition strategy. This is primarily because personal care services, which constitute the majority of Addus's business, are exempt from the moratorium. Allison also believes the government's crackdown on fraud might benefit large, compliant providers like Addus, potentially encouraging smaller agencies to sell.
Addus CEO: Moratorium Has Little To No Impact On Growth, Valuations
Addus HomeCare Corporation's CEO, Dirk Allison, stated that the recently announced moratorium on home health Medicare enrollment will have little to no impact on the company's growth strategy or valuations. This is because the moratorium primarily affects de novo companies, whereas Addus focuses on M&A and organic growth and its personal care services segment is not affected. Allison also noted that the company is actively pursuing acquisitions, including large ones comparable to its $350 million acquisition of Gentiva’s personal care assets.
ADUS Reiterated by Citizens -- Price Target Maintained at $142
Citizens has reiterated a "Market Outperform" rating for Addus HomeCare (ADUS), maintaining its price target at $142.00, despite mixed signals from other analysts. GuruFocus indicates ADUS is currently undervalued with a GF Value™ of $122.66 against a current price of $91.05, and boasts a strong GF Score™ of 93/100 suggesting potential for long-term returns. The company specializes in in-home care services, benefiting from an aging population.
Addus HomeCare Price Target Maintained With a $142.00/Share by Citizens
Citizens has maintained its price target for Addus HomeCare (NASDAQ: ADUS) at $142.00 per share. This indicates a consistent outlook on the company's valuation from the firm.
Citizens reiterates Addus HomeCare stock rating on valuation discount
Citizens has reaffirmed its "Market Outperform" rating and a $142.00 price target for Addus HomeCare (NASDAQ:ADUS), citing a significant valuation discount. The company's stock trades at 8.5x its 2026 EBITDA estimate, considerably below its five-year average, despite strong projected EBITDA growth and favorable regulatory conditions. This reiteration comes after mixed Q1 2026 results, where Addus HomeCare exceeded EPS expectations but missed on revenue.
Citizens reiterates Addus HomeCare stock rating on valuation discount By Investing.com
Citizens has reaffirmed its Market Outperform rating and $142.00 price target for Addus HomeCare (NASDAQ:ADUS), citing a valuation discount. The stock trades at 8.5x its 2026 EBITDA estimate, significantly below its five-year average of 13.4x, despite a projected 15% CAGR for EBITDA from 2021 to 2026. This valuation is seen as not fully reflecting potential upsides from M&A, improved census dynamics, and favorable regulatory conditions, even after a recent revenue miss in Q1 2026.
Addus HomeCare Corporation 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:ADUS) 2026-05-17
Addus HomeCare Corporation (ADUS) has published its slide deck in conjunction with its Q1 2026 earnings call. This presentation provides details related to the company's financial results and operational performance for the quarter ended May 17, 2026. The information is made available to investors and followers of the company on Seeking Alpha.
Addus HomeCare Corp stock (US0067391062): Solid Q1 2026 growth keeps healthcare services in focus
Addus HomeCare Corp reported strong Q1 2026 revenue and earnings growth, driven by continued demand for home-based care and successful integration of acquisitions. The company's business model focuses on personal care, home health, and hospice services, capitalizing on an aging population and the shift towards lower-cost care settings. Investors should monitor state-level funding decisions, operational execution, staffing, and regulatory changes, as these factors significantly influence the company's profitability and growth.
GoodRx, RadNet, Addus HomeCare, Novavax, and Mettler-Toledo Shares Plummet, What You Need To Know
Shares of several healthcare-related companies, including GoodRx, RadNet, Addus HomeCare, Novavax, and Mettler-Toledo, experienced a decline following the April PPI report showing accelerating wholesale inflation. The report indicated a 6% annual inflation rate and the fastest rise in service-sector prices in four years, creating a dual challenge for the healthcare industry through increased operating costs and potential regulatory intervention due to visible price-setting power. Among the impacted stocks, Addus HomeCare's shares fell 3.2%, adding to a year-to-date decline of 11.2%, with a previous drop attributed to a revenue miss in its first-quarter financial results.
Addus HomeCare Corporation (NASDAQ:ADUS) Receives Average Rating of "Moderate Buy" from Analysts
Addus HomeCare Corporation (NASDAQ:ADUS) has received a "Moderate Buy" consensus rating from 11 analysts, with an average 12-month price target of $131.22. The company recently exceeded Q1 earnings estimates with $1.62 per share and saw revenue increase by 7.7% to $363.5 million. Despite some insider selling, institutional investors hold a significant 95.35% stake in the company.
Addus HomeCare Corp stock (US0067391062): 52-week low tests investor patience despite solid earnings
Addus HomeCare Corp (ADUS) stock recently hit a 52-week low near 90 USD despite reporting higher first-quarter revenue and earnings. This disconnect between operational performance and market sentiment is attributed to investor caution regarding reimbursement trends, labor costs, and broader sector rotations. Despite the stock's weakness, analysts maintain a "Moderate Buy" consensus with an average 12-month price target significantly above the current price.
Addus HomeCare stock hits 52-week low at $90.80 By Investing.com
Addus HomeCare Corporation's stock has dropped to a 52-week low of $90.80, marking a 16% decrease over the past year. Despite a "GREAT" financial health score and earnings per share beating analyst expectations, revenue for Q1 2026 fell short, leading Citizens to lower its price target. InvestingPro analysis suggests the stock may be undervalued given its P/E and PEG ratios.
GoodRx, RadNet, Addus HomeCare, Novavax, and Mettler-Toledo Shares Plummet, What You Need To Know
Shares of several healthcare and life sciences companies, including GoodRx, RadNet, Addus HomeCare, Novavax, and Mettler-Toledo, declined after an April PPI report indicated accelerating wholesale inflation, particularly in the service sector. This inflation could increase operating costs for healthcare providers and intensify calls for regulatory intervention on drug pricing. The article highlights that despite the drops, these movements could present buying opportunities for high-quality stocks.
Addus HomeCare (NasdaqGS:ADUS) Stock Forecast & Analyst Predictions
Addus HomeCare (ADUS) is projected to grow earnings and revenue by 11.1% and 4.9% annually, respectively, with EPS expected to increase by 10.6% per year and ROE forecast at 10.6% in three years. Recent updates include a Q1 2026 revenue growth of 7.7% driven by organic growth and Indiana acquisitions, with EPS and revenue meeting analyst expectations. However, analysts have shown a cautious outlook due to updated models and potential regulatory risks from the Medicaid Access Rule, leading to some price target adjustments.
